BARD1 Life Sciences Ltd (ASX:BD1) is a leading Australian-based medical diagnostics company with a deep portfolio of innovative cancer diagnostic technologies and products. The company’s programs are focussed on the development and commercialisation of diagnostic tests for early detection of cancer including ovarian, breast, lung, prostate, bladder and pancreatic cancers. The company is led by a high-calibre Board and experienced leadership team who are advancing the commercial development of four key programs:
An immunocytochemistry (ICC) assay that detects hTERT, a component of telomerase, which is upregulated in most human epithelial cancers. The initial commercial application of the hTERT test is as an adjunct to urine cytology, assisting in the diagnosis of bladder cancer.
A biomarker platform covering various BARD1 tumour markers including nucleic acids, proteins and autoantibodies. The first application is the BARD1 autoantibody tests for early detection of ovarian, breast and lung cancers.
A biomarker capture platform that uses patented Molecular NETs to capture and purify target molecules from patient samples in a scalable, rapid and cost-effective method for utilisation in high throughput laboratories. The SIEN-NET platform enables the Company to access the rapidly growing liquid biopsy market
A pan-cancer probe that is specific for cancer cells and has the potential to complement other technologies and biomarkers to detect cancer using a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.